Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - Nuvectra Corp | ex_101261.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 28, 2017
Nuvectra Corporation
(Exact Name of Registrant as Specified in its Charter)
|
Delaware |
001-37525 |
30-0513847 |
|
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification Number) |
5830 Granite Parkway, Suite 1100,
Plano, Texas 75024
(Address of principal executive offices, including zip code)
(214) 474-3103
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
|
Emerging growth company |
☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
|
Item 8.01 |
Other Events. |
On November 28, 2017, the Company conducted an audio presentation at the 29th Annual Piper Jaffray Healthcare Conference, which was also posted via webcast simultaneously to the Company’s internet website located at www.nuvectramed.com (the “Presentation”). A copy of the transcript of the Presentation is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The Presentation transcript attached as Exhibit 99.1 discloses certain information that is not presented in accordance with United States generally accepted accounting principles (“GAAP”) and may contain certain forward-looking statements, which are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, financial performance, anticipated events and trends, the economy and other future conditions, and therefore they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and may be outside of our control. Our actual financial and operational performance may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. The Company does not comment upon or provide guidance on its quarterly or year-end financials and all financial information related to the Company’s fourth quarter and the financial results for the 2017 fiscal year will be finalized and released following the completion of fiscal year 2017.
|
Item 9.01 |
Financial Statements and Exhibits. |
(d) Exhibits.
|
99.1 |
Transcript of Audio Presentation posted to the Nuvectra website on November 28, 2017. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
November 30, 2017 |
NUVECTRA CORPORATION |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By: |
/s/ Walter Z. Berger |
|
|
|
Name: |
Walter Z. Berger |
|
|
|
Title: |
Chief Operating Officer and Chief Financial Officer |
|